Pure Global

QTX3034 in Patients With KRAS G12D Mutation - Trial NCT06227377

Access comprehensive clinical trial information for NCT06227377 through Pure Global AI's free database. This Phase 1 trial is sponsored by Quanta Therapeutics and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 250 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06227377
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06227377
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
QTX3034 in Patients With KRAS G12D Mutation
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation

Study Focus

Solid Tumors

QTX3034

Interventional

drug

Sponsor & Location

Quanta Therapeutics

San Antonio,Salt Lake City,Fairfax, United States of America

Timeline & Enrollment

Phase 1

Feb 05, 2024

Apr 01, 2027

250 participants

Primary Outcome

Number of participants with Dose Limiting Toxicities (DLTs),Number of participants with Treatment-emergent Adverse Events (TEAEs)

Summary

Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in
 combination with cetuximab.

ICD-10 Classifications

Malignant neoplasm: Connective and soft tissue, unspecified
Malignant neoplasm of other connective and soft tissue
Carcinoma in situ, unspecified
Malignant neoplasms
Malignant neoplasm: Parametrium

Data Source

ClinicalTrials.gov

NCT06227377

Non-Device Trial